Dissemination of Subject Data and Research Materials. To the extent permitted by law, the Collaborator and PHS agree to use reasonable efforts to keep Subject Data and Research Materials confidential until published or until corresponding patent applications are filed. Any information that would identify human subjects of research or patients will always be maintained confidentially. To the extent permitted by law, the Collaborator shall have the exclusive right to use any and all CRADA Subject Data in and for any regulatory filing by or on behalf of Collaborator, except that PHS shall have the exclusive right to use Subject Data for that purpose, and authorize others to do so, if the CRADA is terminated or if Collaborator abandons its commercialization efforts. Collaborator acknowledges the basic research mission of the PHS, and agrees that after publication, PHS may make unpatented research materials arising out of this CRADA available to third parties for further research.
Dissemination of Subject Data and Research Materials. To the extent allowed under law, the Collaborator and PHS agree to use reasonable efforts to keep Subject Data and Research Materials confidential until published or until corresponding patent applications are filed. Any information that would identify human subjects of research or patients will always be maintained confidentially. Collaborator shall have the exclusive right to use any and all CRADA Subject Data in and for any regulatory filing by or on behalf of Collaborator, except that PHS shall have the exclusive right to use Subject Data for that purpose, and authorize others to do so, if the CRADA is terminated or if Collaborator abandons its commercialization efforts.
Dissemination of Subject Data and Research Materials. To the extent permitted by law, the Collaborator and PHS agree to use reasonable efforts to keep Subject Data and Research Materials confidential until published (subject to the terms of Article 87) or until corresponding patent applications are filed. Any information that would identify human subjects of research or patients will always be maintained confidentially. To the extent permitted by law, the Collaborator shall have the exclusive right to use any and all CRADA Subject Data in and for any regulatory filing by or on behalf of Collaborator, except that PHS shall have the exclusive right to use Subject Data for that purpose, and authorize others to do so, if the CRADA is terminated or if Collaborator abandons its commercialization efforts related to the Study Drug. Collaborator acknowledges the basic research mission of the PHS, and agrees that after publication, PHS may make unpatented Research Materials arising out of this CRADA available to third parties for further research.
8.4 to read as follows:
Dissemination of Subject Data and Research Materials. To the extent allowed under law, RPRP, Introgen and PHS agree to use reasonable efforts to keep Subject Data and Research Materials confidential until published or until corresponding patent applications are filed. Any information that would identify human subjects of research or patients will always be maintained confidentially. To the extent permitted by law, RPRP and Introgen, respectively, shall have the co-exclusive right to use any and all CRADA Subject Data in and for any regulatory filing, or for any commercialization purpose, consistent with Articles 8.7 and 13.10, except that PHS shall have the exclusive right to use Subject Data for said purpose/s, and authorize others to do so, if the CRADA is terminated or if RPRP and Introgen abandon their commercialization efforts consistent with the terms of Section 10.6.
Dissemination of Subject Data and Research Materials. To the extent permitted by law, the Collaborator and NCI agree to use reasonable efforts to keep Subject Data and Research Materials confidential until published or until corresponding patent applications are filed. Any information that would identify human subjects of research or patients will always be maintained confidentially. To the extent permitted by law, the Collaborator shall have the exclusive right to use any and all CRADA Subject Data in and for any regulatory filing by or on behalf of Collaborator, except that NCI shall have the exclusive right to use Subject Data for that purpose, and authorize others to do so, if the CRADA is terminated or if Collaborator abandons its commercialization efforts. * Confidential treatment requested: material has been omitted and filed separately with the Commission.
Dissemination of Subject Data and Research Materials. To the extent permitted by law, the Collaborator and TGen agree to use reasonable efforts to keep Subject Data and Research Materials confidential until published or until corresponding patent applications are filed. Any information that would identify human subjects of research or patients will always be maintained confidentially. To the extent permitted by law, the Collaborator shall have the exclusive right to use any and all Agreement Subject Data in and for any regulatory filing by or on behalf of Collaborator, except that TGen shall have the exclusive right to use Subject Data for that purpose, and authorize others to do so if the Agreement is terminated or if Collaborator abandons its commercialization efforts. Collaborator acknowledges the basic research mission of TGen, and agrees that, after publication, TGen may make unpatented research materials arising out of this Agreement available to third parties for further research.
Dissemination of Subject Data and Research Materials. To the extent permitted by law, the Collaborator and PHS agree to use reasonable efforts to keep Subject Data and Research Materials confidential until published or until corresponding patent applications are filed. Any information that would identify human subjects of research or patients will always be maintained confidentially. To the extent permitted by law and subject to the other provisions of Article 8.
Dissemination of Subject Data and Research Materials. To the extent allowed under law, the Collaborators, Foundation, and USU agree to use reasonable efforts to keep Subject Data and Research Materials confidential until published or until corresponding patent applications are filed. Any information that would identify human subjects of research or patients will be maintained confidentially and in compliance with all applicable laws and regulations, including without limitation the Health Insurance Portability and Accountability Act of 1996 (HIPAA), as amended, and its implementing regulations. To the extent permitted by law, the Collaborators shall have the exclusive right to use any and all Subject Data in and for any regulatory filing by or on behalf of the Collaborators, except that Foundation and USU shall have the exclusive right to use Subject Data for that purpose, and authorize others to do so, if the CRADA is terminated or if the Collaborators abandon their commercialization efforts.
Dissemination of Subject Data and Research Materials. To the extent allowed under law, UAB agrees to use the same degree of care as UAB uses for its own proprietary/confidential information to keep Subject Data and Research Materials confidential, until published or until corresponding patent applications are filed. UAB may delay disclosure of Subject Data for a reasonable time in order for patent applications to be filed. Generally, UAB will not further limit disclosure of Subject Data or Research Materials.
Dissemination of Subject Data and Research Materials. To the extent permitted by law, the Collaborator and Academia Sinica agree to use reasonable efforts to keep Subject Data and Research Materials confidential until published or until corresponding patent applications are filed. Any information that would identify human subjects of research or patients will always be maintained confidentially. Collaborator shall have the exclusive right to use any and all CRADA Subject Data in and for any regulatory filing by or on behalf of Collaborator, except that Academia Sinica shall have the exclusive right to use Subject Data for that purpose, and authorize others to do so, if the CRADA is terminated or if Collaborator abandons its commercialization efforts.
